- •Preface and Acknowledgments
- •Contents
- •Contributors
- •1: Embryology for Urologists
- •Introduction
- •Renal Development
- •Pronephros
- •Mesonephros
- •Metanephros
- •Development of the Collecting System
- •Critical Steps in Further Development
- •Anomalies of the Kidney
- •Renal Agenesis
- •Renal Aplasia
- •Renal Hypoplasia
- •Renal Ectopia
- •Renal Fusion
- •Ureteral Development
- •Anomalies of Origin
- •Anomalies of Number
- •Incomplete Ureteral Duplication
- •Complete Ureteral Duplication
- •Ureteral Ectopia
- •Embryology of Ectopia
- •Clinical Correlation
- •Location of Ectopic Ureteral Orifices – Male (in Descending Order According to Incidence)
- •Symptoms
- •Ureteroceles
- •Congenital Ureteral Obstruction
- •Pipestem Ureter
- •Megaureter-Megacystis Syndrome
- •Prune Belly Syndrome
- •Vascular Ureteral Obstructions
- •Division of the Urogenital Sinus
- •Bladder Development
- •Urachal Anomalies
- •Cloacal Duct Anomalies
- •Other Bladder Anomalies
- •Bladder Diverticula
- •Bladder Extrophy
- •Gonadal Development
- •Testicular Differentiation
- •Ovarian Differentiation
- •Gonadal Anomalies
- •Genital Duct System
- •Disorders of Testicular Function
- •Female Ductal Development
- •Prostatic Urethral Valves
- •Gonadal Duct Anomalies
- •External Genital Development
- •Male External Genital Development
- •Female External Genital Development
- •Anomalies of the External Genitalia
- •References
- •2: Gross and Laparoscopic Anatomy of the Upper Urinary Tract and Retroperitoneum
- •Overview
- •The Kidneys
- •The Renal Vasculature
- •The Renal Collecting System
- •The Ureters
- •Retroperitoneal Lymphatics
- •Retroperitoneal Nerves
- •The Adrenal Glands
- •References
- •3: Gross and Laparoscopic Anatomy of the Lower Urinary Tract and Pelvis
- •Introduction
- •Female Pelvis
- •Male Pelvis
- •Pelvic Floor
- •Urinary Bladder
- •Urethra
- •Male Urethra
- •Female Urethra
- •Sphincter Mechanisms
- •The Bladder Neck Component
- •The Urethral Wall Component
- •The External Urethral Sphincter
- •Summary
- •References
- •4: Anatomy of the Male Reproductive System
- •Testis and Scrotum
- •Spermatogenesis
- •Hormonal Regulation of Spermatogenesis
- •Genetic Regulation of Spermatogenesis
- •Epididymis and Ductus Deferens
- •Accessory Sex Glands
- •Prostate
- •Seminal Vesicles
- •Bulbourethral Glands
- •Penis
- •Erection and Ejaculation
- •References
- •5: Imaging of the Upper Tracts
- •Anatomy of the Upper Tracts and Introduction to Imaging Modalities
- •Introduction
- •Renal Upper Tract Basic Anatomy
- •Modalities Used for Imaging the Upper Tracts
- •Ultrasound
- •Radiation Issues
- •Contrast Issues
- •Renal and Upper Tract Tumors
- •Benign Renal Tumors
- •Transitional Cell Carcinoma
- •Renal Mass Biopsy
- •Renal Stone Disease
- •Ultrasound
- •Plain Radiographs and IVU
- •Renal Cystic Disease
- •Benign Renal Cysts
- •Hereditary Renal Cystic Disease
- •Complex Renal Cysts
- •Renal Trauma
- •References
- •Introduction
- •Pathophysiology
- •Susceptibility and Resistance
- •Epidemiological Breakpoints
- •Clinical Breakpoints
- •Pharmacodynamic Parameters
- •Pharmacokinetic Parameters
- •Fosfomycin
- •Nitrofurantoin
- •Pivmecillinam
- •b-Lactam-Antibiotics
- •Penicillins
- •Cephalosporins
- •Carbapenems
- •Aminoglycosides
- •Fluoroquinolones
- •Trimethoprim, Cotrimoxazole
- •Glycopeptides
- •Linezolid
- •Conclusion
- •References
- •7: An Overview of Renal Physiology
- •Introduction
- •Body Fluid Compartments
- •Regulation of Potassium Balance
- •Regulation of Acid–Base Balance
- •Diuretics
- •Suggested Reading
- •8: Ureteral Physiology and Pharmacology
- •Ureteral Anatomy
- •Modulation of Peristalsis
- •Ureteral Pharmacology
- •Conclusion
- •References
- •Introduction
- •Afferent Signaling Pathways
- •Efferent Signaling
- •Parasympathetic Nerves
- •Sympathetic Nerves
- •Vesico-Spinal-Vesical Micturition Reflex
- •Peripheral Targets
- •Afferent Signaling Mechanisms
- •Urothelium
- •Myocytes
- •Cholinergic Receptors
- •Muscarinic Receptors
- •Nicotinic Receptors
- •Adrenergic Receptors (ARs)
- •a-Adrenoceptors
- •b-Adrenoceptors
- •Transient Receptor Potential (TRP) Receptors
- •Phosphodiesterases (PDEs)
- •CNS Targets
- •Opioid Receptors
- •Serotonin (5-HT) Mechanisms
- •g-Amino Butyric Acid (GABA) Mechanisms
- •Gabapentin
- •Neurokinin and Neurokinin Receptors
- •Summary
- •References
- •10: Pharmacology of Sexual Function
- •Introduction
- •Sexual Desire/Arousal
- •Endocrinology
- •Steroids in the Male
- •Steroids in the Female
- •Neurohormones
- •Neurotransmitters
- •Dopamine
- •Serotonin
- •Pharmacological Strategies
- •CNS Drugs
- •Enzyme-inducing Antiepileptic Drugs
- •Erectile Function
- •Ejaculatory Function
- •Premature Ejaculation
- •Abnormal Ejaculation
- •Conclusions
- •References
- •Epidemiology
- •Calcium-Based Urolithiasis
- •Uric Acid Urolithiasis
- •Infectious Urolithiasis
- •Cystine-Based Urolithiasis
- •Aims
- •Who Deserves Metabolic Evaluation?
- •Metabolic Workup for Stone Producers
- •Medical History and Physical Examination
- •Stone Analysis
- •Serum Chemistry
- •Urine Evaluation
- •Urine Cultures
- •Urinalysis
- •Twenty-Four Hour Urine Collections
- •Radiologic Imaging
- •Medical Management
- •Conservative Management
- •Increased Fluid Intake
- •Citrus Juices
- •Dietary Restrictions
- •Restricted Oxalate Diet
- •Conservative Measures
- •Selective Medical Therapy
- •Absorptive Hypercalciuria
- •Thiazide
- •Orthophosphate
- •Renal Hypercalciuria
- •Primary Hyperparathyroidism
- •Hyperuricosuric Calcium Oxalate Nephrolithiasis
- •Enteric Hyperoxaluria
- •Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Distal Renal Tubular Acidosis
- •Chronic Diarrheal States
- •Thiazide-Induced Hypocitraturia
- •Idiopathic Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Hypomagnesiuric Calcium Nephrolithiasis
- •Gouty Diathesis
- •Cystinuria
- •Infection Lithiasis
- •Summary
- •References
- •12: Molecular Biology for Urologists
- •Introduction
- •Inherited Changes in Cancer Cells
- •VEGR and Cell Signaling
- •Targeting mTOR
- •Conclusion
- •References
- •13: Chemotherapeutic Agents for Urologic Oncology
- •Introduction
- •Bladder Cancer
- •Muscle Invasive Bladder Cancer
- •Metastatic Bladder Cancer
- •Conclusion
- •Prostate Cancer
- •Other Chemotherapeutic Drugs or Combinations for Treating HRPC
- •Conclusion
- •Renal Cell Carcinoma
- •Chemotherapy
- •Immunotherapy
- •Angiogenesis Inhibitor Drugs
- •Conclusion
- •Testicular Cancer
- •Stage I Seminoma
- •Stage I non-seminomatous Germ Cell Tumours (NSGCT)
- •Metastatic Germ Cell Tumours
- •Low-Volume Metastatic Disease (Stage II A/B)
- •Advanced Metastatic Disease
- •Salvage Chemotherapy for Relapsed or Refractory Disease
- •Conclusion
- •Penile Cancer
- •Side Effects of Chemotherapy
- •Conclusion
- •References
- •14: Tumor and Transplant Immunology
- •Antibodies
- •Cytotoxic and T-helper Cells
- •Immunosuppression
- •Induction Therapy
- •Maintenance Therapy
- •Rejection
- •Posttransplant Lymphoproliferative Disease
- •Summary
- •References
- •15: Pathophysiology of Renal Obstruction
- •Causes of Renal Obstruction
- •Effects on Prenatal Development
- •Prenatal Hydronephrosis
- •Spectrum of Renal Abnormalities
- •Renal Functional Changes
- •Renal Growth/Counterbalance
- •Vascular Changes
- •Inflammatory Mediators
- •Glomerular Development Changes
- •Mechanical Stretch of Renal Tubules
- •Unilateral Versus Bilateral
- •Limitations of Animal Models
- •Future Research
- •Issues in Patient Management
- •Diagnostic Imaging
- •Ultrasound
- •Intravenous Urography
- •Antegrade Urography and the Whitaker Test
- •Nuclear Renography
- •Computed Tomography
- •Magnetic Resonance Urography
- •Hypertension
- •Postobstructive Diuresis
- •References
- •Introduction
- •The Normal Lower Urinary Tract
- •Anatomy
- •Storage Function
- •Voiding Function
- •Neural Control
- •Symptoms
- •Flow Rate and Post-void Residual
- •Voiding Cystometry
- •Male
- •Female
- •Neurourology
- •Conclusions
- •References
- •17: Urologic Endocrinology
- •The Testis
- •Normal Androgen Metabolism
- •Epidemiological Aspects
- •Prostate
- •Brain
- •Muscle Mass and Adipose Tissue
- •Bones
- •Ematopoiesis
- •Metabolism
- •Cardiovascular System
- •Clinical Assessment
- •Biochemical Assessment
- •Treatment Modalities
- •Oral Preparations
- •Parenteral Preparations
- •Transdermal Preparations
- •Side Effects and Treatment Monitoring
- •Body Composition
- •Cognitive Decline
- •Bone Metabolism
- •The Kidneys
- •Endocrine Functions of the Kidney
- •Erythropoietin
- •Calcitriol
- •Renin
- •Paraneoplastic Syndromes
- •Hypercalcemia
- •Hypertension
- •Polycythemia
- •Other Endocrine Abnormalities
- •References
- •General Physiology
- •Prostate Innervation
- •Summary
- •References
- •Wound Healing
- •Inflammation
- •Proliferation
- •Remodeling
- •Principles of Plastic Surgery
- •Tissue Characteristics
- •Grafts
- •Flap
- •References
- •Lower Urinary Tract Symptoms
- •Storage Phase
- •Voiding Phase
- •Return to Storage Phase
- •Urodynamic Parameters
- •Urodynamic Techniques
- •Volume Voided Charts
- •Pad Testing
- •Typical Test Schedule
- •Uroflowmetry
- •Post Voiding Residual
- •Further Diagnostic Evaluation of Patients
- •Cystometry with or Without Video
- •Cystometry
- •Videocystometrography (Cystometry + Cystourethrography)
- •Cystometric Findings
- •Comment:
- •Measurements During the Storage Phase:
- •Measurements During the Voiding Phase:
- •Abnormal Function
- •Disorders of Sensation
- •Causes of Hypersensitive Bladder Sensation
- •Causes of Hyposensitive Bladder Sensation
- •Disorders of Detrusor Motor Function
- •Bladder Outflow Tract Dysfunction
- •Detrusor–Urethral Dyssynergia
- •Detrusor–Bladder Neck Dyssynergia
- •Detrusor–Sphincter Dyssynergia
- •Complex Urodynamic Investigation
- •Urethral Pressure Measurement
- •Technique
- •Neurophysiological Evaluation
- •Conclusion
- •References
- •Endoscopy
- •Cystourethroscopy
- •Ureteroscopy and Ureteropyeloscopy
- •Nephroscopy
- •Virtual Reality Simulators
- •Lasers
- •Clinical Application of Lasers
- •Condylomata Acuminata
- •Urolithiasis
- •Benign Prostatic Hyperplasia
- •Ureteral and Urethral Strictures
- •Conclusion
- •References
- •Introduction
- •The Prostatitis Syndromes
- •The Scope of the Problem
- •Category III CP/CPPS
- •The Goal of Treatment
- •Conservative Management
- •Drug Therapy
- •Antibiotics
- •Anti-inflammatories
- •Alpha blockers
- •Hormone Therapies
- •Phytotherapies
- •Analgesics, muscle relaxants and neuromodulators
- •Surgery
- •A Practical Management Plan
- •References
- •Orchitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment of Infectious Orchitis
- •Epididymitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation of Epididymitis
- •Treatment of Acute Epididymitis
- •Treatment of Chronic Epididymitis
- •Treatment of Spermatic Cord Torsion
- •Fournier’s Gangrene
- •Definition and Etiology
- •Risk Factors
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment
- •References
- •Fungal Infections
- •Candidiasis
- •Aspergillosis
- •Cryptococcosis
- •Blastomycosis
- •Coccidioidomycosis
- •Histoplasmosis
- •Radiographic Findings
- •Treatment
- •Tuberculosis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Schistosomiasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Filariasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Onchocerciasis
- •References
- •25: Sexually Transmitted Infections
- •Introduction
- •STIs Associated with Genital Ulcers
- •Herpes Simplex Virus
- •Diagnosis
- •Treatment
- •Chancroid
- •Diagnosis
- •Treatment
- •Syphilis
- •Diagnosis
- •Treatment
- •Lymphogranuloma Venereum
- •Diagnosis
- •Treatment
- •Chlamydia
- •Diagnosis
- •Treatment
- •Gonorrhea
- •Diagnosis
- •Treatment
- •Trichomoniasis
- •Diagnosis
- •Treatment
- •Human Papilloma Virus
- •Diagnosis
- •Treatment
- •Scabies
- •Diagnosis
- •Treatment
- •References
- •26: Hematuria: Evaluation and Management
- •Introduction
- •Classification of Hematuria
- •Macroscopic Hematuria
- •Microscopic Hematuria
- •Dipstick Hematuria
- •Pseudohematuria
- •Factitious Hematuria
- •Menstruation
- •Aetiology
- •Malignancy
- •Urinary Calculi
- •Infection and Inflammation
- •Benign Prostatic Hyperplasia
- •Trauma
- •Drugs
- •Nephrological Causes
- •Assessment
- •History
- •Examination
- •Investigations
- •Dipstick Urinalysis
- •Cytology
- •Molecular Tests
- •Blood Tests
- •Flexible Cystoscopy
- •Upper Urinary Tract Evaluation
- •Renal USS
- •KUB Abdominal X-Ray
- •Intravenous Urography (IVU)
- •Computed Tomography (CT)
- •Retrograde Urogram Studies
- •Magnetic Resonance Imaging (MRI)
- •Additional Tests and Renal Biopsy
- •Intractable Hematuria
- •Loin Pain Hematuria Syndrome
- •References
- •27: Benign Prostatic Hyperplasia (BPH)
- •Historical Background
- •Pathophysiology
- •Patient Assessment
- •Treatment of BPH
- •Watchful Waiting
- •Drug Therapy
- •Interventional Therapies
- •Conclusions
- •References
- •28: Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie´s Disease
- •Erectile Dysfunction
- •Introduction
- •Diagnosis
- •Basic Evaluation
- •Cardiovascular System and Sexual Activity
- •Optional Tests
- •Treatment
- •Medical Treatment
- •Oral Agents
- •Phosphodiesterase Type 5 (PDE 5) Inhibitors
- •Nonresponders to PDE5 Inhibitors
- •Apomorphine SL
- •Yohimbine
- •Intracavernosal and Intraurethral Therapy
- •Intracavernosal Injection (ICI) Therapy
- •Intraurethral Therapy
- •Vacuum Constriction Devices
- •Surgical Therapy
- •Conclusion
- •Peyronie´s Disease (PD)
- •Introduction
- •Oral Drug Therapy
- •Intralesional Drug Therapy
- •Iontophoresis
- •Radiation Therapy
- •Surgical Therapy
- •References
- •29: Premature Ejaculation
- •Introduction
- •Epidemiology
- •Defining Premature Ejaculation
- •Voluntary Control
- •Sexual Satisfaction
- •Distress
- •Psychosexual Counseling
- •Pharmacological Treatment
- •On-Demand Treatment with Tramadol
- •Topical Anesthetics
- •Phosphodiesterase Inhibitors
- •Surgery
- •Conclusion
- •References
- •30: The Role of Interventional Management for Urinary Tract Calculi
- •Contraindications to ESWL
- •Complications of ESWL
- •PCNL Access
- •Instrumentation for PCNL
- •Nephrostomy Drains Post PCNL
- •Contraindications to PCNL
- •Complications of PCNL
- •Semirigid Ureteroscopy
- •Flexible Ureteroscopy
- •Electrohydraulic Lithotripsy (EHL)
- •Ultrasound
- •Ballistic Lithotripsy
- •Laser Lithotripsy
- •Ureteric Stents
- •Staghorn Calculi
- •Lower Pole Stones
- •Horseshoe Kidneys and Stones
- •Calyceal Diverticula Stones
- •Stones and PUJ Obstruction
- •Treatment of Ureteric Colic
- •Medical Expulsive Therapy (MET)
- •Intervention for Ureteric Stones
- •Stones in Pregnancy
- •Morbid Obesity
- •References
- •Anatomy and Function
- •Pathophysiology
- •Management
- •Optical Urethrotomy/Dilatation
- •Urethral Stents
- •Preoperative Assessment
- •Urethroplasty
- •Anastomotic Urethroplasty
- •Substitution Urethroplasty
- •Grafts Versus Flaps
- •Oral Mucosal Grafts
- •Tissue Engineering
- •Graft Position
- •Conclusion
- •References
- •32: Urinary Incontinence
- •Epidemiology and Risk Factors
- •Pathophysiology
- •Urge Incontinence
- •Conservative Treatments
- •Pharmacotherapy
- •Invasive/ Surgical Therapies
- •Stress Urinary Incontinence
- •Male SUI Therapies
- •Female SUI Therapies
- •Mixed Urinary Incontinence
- •Conclusions
- •References
- •33: Neurogenic Bladder
- •Introduction
- •Examination and Diagnostic Tests
- •History and Physical Examination
- •Imaging
- •Urodynamics (UDS)
- •Evoked Potentials
- •Classifications
- •Somatic Pathways
- •Brain Lesions
- •Cerebrovascular Accident (CVA)
- •Parkinson’s Disease (PD)
- •Multiple Sclerosis
- •Huntington’s Disease
- •Dementias
- •Normal Pressure Hydrocephalus (NPH)
- •Tumors
- •Psychiatric Disorders
- •Spinal Lesions and Pathology
- •Intervertebral Disk Prolapse
- •Spinal Cord Injury (SCI)
- •Transverse Myelitis
- •Peripheral Neuropathies
- •Metabolic Neuropathies
- •Pelvic Surgery
- •Treatment
- •Summary
- •References
- •34: Pelvic Prolapse
- •Introduction
- •Epidemiology
- •Anatomy and Pathophysiology
- •Evaluation and Diagnosis
- •Outcome Measures
- •Imaging
- •Urodynamics
- •Indications for Management
- •Biosynthetics
- •Surgical Management
- •Anterior Compartment Repair
- •Uterine/Apical Prolapse
- •Enterocele Repair
- •Conclusion
- •References
- •35: Urinary Tract Fistula
- •Introduction
- •Urogynecologic Fistula
- •Vesicovaginal Fistula
- •Etiology and Risk Factors
- •Clinical Factors
- •Evaluation and Diagnosis
- •Pelvic Examination
- •Cystoscopy
- •Imaging
- •Treatment
- •Conservative Management
- •Surgical Management
- •Urethrovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Ureterovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Vesicouterine Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Uro-Enteric Fistula
- •Vesicoenteric Fistula
- •Pyeloenteric Fistula
- •Urethrorectal Fistula
- •References
- •36: Urologic Trauma
- •Introduction
- •Kidney
- •Expectant Management
- •Endovascular Therapy
- •Operative Intervention
- •Operative Management: Follow-up
- •Reno-Vascular Injuries
- •Pediatric Renal Injuries
- •Adrenal
- •Ureter
- •Diagnosis
- •Treatment
- •Delayed Diagnosis
- •Bladder and Posterior Urethra
- •Bladder Injuries: Initial Management
- •Bladder Injuries: Formal Repair
- •Anterior Urethral Trauma
- •Fractured Penis
- •Penile Amputation
- •Scrotal and Testicular Trauma
- •Imaging
- •CT-IVP (CT with Delayed Images)
- •Technique
- •Cystogram
- •Technique
- •Retrograde Urethrogram (RUG)
- •Technique
- •Retrograde Pyelogram (RPG)
- •Technique
- •One-Shot IVP
- •Technique
- •References
- •37: Bladder Cancer
- •Who Should Be Investigated?
- •Epidemiology
- •Risk Factors
- •Role of Screening
- •Signs and Symptoms
- •Imaging
- •Cystoscopy
- •Urine Tests
- •PDD-Assisted TUR
- •Pathology
- •NMIBC and Risk Groups
- •Intravesical Chemotherapy
- •Intravesical Immunotherapy
- •Immediate Cystectomy and CIS
- •Radical Cystectomy with Pelvic Lymph Node Dissection
- •sexual function-preserving techniques
- •Bladder-Preservation Treatments
- •Neoadjuvant Chemotherapy
- •Adjuvant Chemotherapy
- •Preoperative Radiotherapy
- •Follow-up After TUR in NMIBC
- •References
- •38: Prostate Cancer
- •Introduction
- •Epidemiology
- •Race
- •Geographic Variation
- •Risk Factors and Prevention
- •Family History
- •Diet and Lifestyle
- •Prevention
- •Screening and Diagnosis
- •Current Screening Recommendations
- •Biopsy
- •Pathology
- •Prognosis
- •Treatment of Prostate Cancer
- •Treatment for Localized Prostate Cancer (T1, T2)
- •Radical Prostatectomy
- •EBRT
- •IMRT
- •Brachytherapy
- •Treatment for Locally Advanced Prostate Cancer (T3, T4)
- •EBRT with ADT
- •Radical Prostatectomy
- •Androgen-Deprivation Therapy
- •Summary
- •References
- •39: The Management of Testis Cancer
- •Presentation and Diagnosis
- •Serum Tumor Markers
- •Primary Surgery
- •Testis Preserving Surgery
- •Risk Stratification
- •Surveillance Versus Primary RPLND
- •Primary RPLND
- •Adjuvant Treatment for High Risk
- •Clinical Stage 1 Seminoma
- •Risk-Stratified Adjuvant Treatment
- •Adjuvant Radiotherapy
- •Adjuvant Low Dose Chemotherapy
- •Primary Combination Chemotherapy
- •Late Toxicity
- •Salvage Strategies
- •Conclusion
- •References
- •Index
223
Urologic Endocrinology
Prostate |
androgen replacement on cognition in older |
||||||
Testosterone is known to be the major growth |
testosterone-deficient men are needed, as are |
||||||
studies on the benefits on cognitive function in |
|||||||
and functional regulator of the prostate and is |
|||||||
dementia associated with aging.37 |
|
|
|
||||
essential to the development and maintenance |
|
|
|
|
|
|
|
of this organ throughout life. Prostate develop- |
Muscle Mass and Adipose Tissue |
|
|
|
|||
ment, differentiation and maintenance are |
|
|
|
||||
known to be closely linked to the bioavailability |
Testosterone is known to increase muscle pro- |
||||||
of testosterone and other related sex hormones. |
|||||||
tein synthesis and increase muscle strength.38 |
|||||||
Between the ages of 10–20 years when serum |
Muscle mass is also correlated with serum tes- |
||||||
testosterone levels rise dramatically in males, |
|||||||
tosterone and free testosterone in older men |
|||||||
there is a pronounced, exponential growth of |
|||||||
whereas data on muscle strength is not con- |
|||||||
the prostate controlled by the balanced agonist |
|||||||
clusive.39 |
Testosterone |
deficiency |
results |
in |
|||
and antagonist abilities of androgens to stimu- |
decreased muscle mass and strength in hypogo- |
||||||
late cell proliferation on the one hand, and to |
|||||||
nadal young and middle-aged men. Multiple |
|||||||
inhibit the rate of cell death in prostate tissue on |
|||||||
non-placebo-controlled |
studies have |
demon- |
|||||
the other.After the age of 20, and under the con- |
|||||||
strated the positive effects of androgen replace- |
|||||||
tinuing presence of testosterone, the healthy |
|||||||
ment on these functions in these age groups.38 |
|||||||
prostate achieves a steady state of self-renewal |
In several reported studies that included men |
||||||
and maintenance.30 Within the prostate, testos- |
|||||||
with low baseline testosterone levels, testoster- |
|||||||
terone is enzymatically converted to an active |
|||||||
one treatment in older men increased muscle |
|||||||
metabolite, 5a-dihydrotestosterone (DHT), by |
|||||||
mass.27,40 |
Testosterone |
replacement |
therapy |
||||
5a-reductase. Once formed, DHT can bind |
results in decreased abdominal fat and total fat |
||||||
reversibly to the androgen receptor to regulate |
|||||||
mass in elderly men.41 Rajan et al hypothesized |
|||||||
prostatic cellular proliferation and survival. It is |
that testosterone may regulate body composi- |
||||||
thought that normally the prostatic level of |
|||||||
tion by preferentially inducing pluripotent mes- |
|||||||
DHT remains constant even during diurnal and |
|||||||
enchymal cell differentiation toward a myogenic |
|||||||
episodic variations in the serum levels of both |
|||||||
lineage and away from an adipogenic lineage.42 |
|||||||
free and total testosterone. The presence of DHT |
|
|
|
|
|
|
|
and its binding to androgen receptors can |
Bones |
|
|
|
|
|
|
directly up-regulate the expression of prostate- |
|
|
|
|
|
||
specific differentiation markers such as PSA |
Androgen receptors are present on osteoblasts, |
||||||
and locally active growth factors known as |
|||||||
and androgens are known to stimulate osteo- |
|||||||
andromedins.31 |
|||||||
blast differentiation in utero.43 The beneficial |
|||||||
|
|||||||
|
effects of androgens on bone may be secondary |
||||||
Brain |
to their aromatization to estrogen or through |
||||||
the anabolic affects of dihydrotestosterone. |
|||||||
Androgens have been shown to enhance both |
|||||||
Dihydrotestosterone enhances mitogenesis |
in |
||||||
memory and spacial skills in rats.32 Some epide- |
bone cells by inducing the transforming growth |
||||||
miological studies have found correlations |
factor beta mRNA and by enhancing the binding |
||||||
between serum testosterone levels and general |
of the insulin-like growth factor II to osteoblasts. |
||||||
or spatial cognition.33 Experimental data exists |
Moreover, androgens inhibit the expression of |
||||||
demonstrating that 5 alpha-reduced metabolites |
interleukin-6, also known as osteoclast activat- |
||||||
of T may have effects in the hippocampus that |
ing factor.44 Studies have demonstrated a clear |
||||||
result in enhanced cognitive performance; how- |
correlation between bioavailable |
testosterone |
|||||
ever, it remains still unknown whether DHT or |
and bone mineral density.45,46 A direct link |
||||||
T can improve or maintain cognitive func- |
between testosterone deficiency in aging males |
||||||
tion.34,35 Hypogonadal young and middle-aged |
and hip fracture was demonstrated in a casecon- |
||||||
men frequently complain of symptoms of dep- |
trol study showing that 48% of subjects with hip |
||||||
ression and a decreased sense of well-being and |
fractures were hypogonadal, compared with |
||||||
non-placebo-controlled studies have suggested |
only 12% of a control group; a statistically sig- |
||||||
that mood is improved after testosterone treat- |
nificant difference.47 The association between |
||||||
ment.36 More detailed studies of the effect of |
hypogonadism and hip fractures was confirmed |
|
|
224 |
|
|
|
|
|
Practical Urology: EssEntial PrinciPlEs and PracticE |
in another study on aging men, and it was sug- |
and testosterone administration results in lipol- |
|
gested that early diagnosis and treatment of |
ysis. Testosterone replacement in hypogonadal |
|
hypogonadism might prevent hip fractures in |
men with abdominal obesity enhances triglycer- |
|
an aging population.48 Additional potential con- |
ide turnover in abdominal adipose tissue.54 |
|
tributing mechanisms are increased mechanical |
|
|
loading via anabolic effects on muscle. |
Cardiovascular System |
|
|
|
Ematopoiesis
Androgens stimulate erythropoiesis in mammallians by enhancing renal erythropoietin production by means of receptor-mediated transcription and by a direct effect on erythropoietic stem cells in the bone marrow.Androgen receptors are present on cultured erythroblasts and exogenous androgens have direct stimulatory effects on bone marrow stem cells.49,50 Testosterone also enhances the production of heme and globin. Testosterone deficiency results in a 10–20% decrease in the blood hemoglobin concentration which can bring about anemia. Young hypogonadal men usually have fewer red blood cells and lower hemoglobin levels than age-matched controls, while healthy older men may also have lower hemoglobin levels than normal young men.51
Metabolism
Observational studies support the hypothesis that low testosterone is a component of a multidimensional metabolic syndrome characterized by obesity, diabetes mellitus, hypertension, dyslipidemia and a procoagulant/antifibrinolytic state. At physiological doses, testosterone is known to have beneficial effects on glucose regulation. In human studies of obese, diabetic and hypogonadal men, testosterone administration resulted in decreased fasting glucose, increased insulin sensitivity and decreased glycosylatedhemoglobin A1.52 Laaksonen et al reported that hypogonadism can predict the subsequent development of diabetes and metabolic syndrome in middle aged men. They also hypothesized that, in addition to being an early marker of metabolic syndrome or overt diabetes, hypogonadism may also be involved in the pathogenesis of these disease processes.53 Hypogonadism was associated with abdominal obesity. Testosterone levels were negatively associated with levels of triglycerides and lipoprotein (a) and positively correlated with HDL levels. Androgen receptors have been identified on adipocytes,
In recent years exciting evidence has proven that androgens favorably influence cardiovascular risk through their influence on arteriosclerosis55 . Beyond the beneficial effects on cardiovascular risk profile, Testosterone has been reported to exert direct effects on cardiovascular tissues. Both classical genomic (nuclear androgen-recep- tor mediated) and rapid, non-genomic (mediated by membrane androgen receptor) signaling pathways have been described as mediating the effects of Testosterone on the cardiovascular system.56 Testosterone exerts acute vasorelaxant effects on peripheral and coronary circulation by modulating membrane ion-channel function. Moreover, physiological testosterone levels are involved in vascular structural homeostasis preservation. Testosterone has been reported to promote endothelial integrity through stimulating endothelial progenitor cells within the bone marrow to proliferate, migrate into the peripheral blood and repair endothelium when injuried.57 Moreover, physiological testosterone levels inhibit vascular smooth muscle cell proliferation and migration thereby counteracting atheroscleroticrelated processes such as neointima formation and media thickening.58
Male Hypogonadism: Diagnosis
and Treatment
In addition to an adequate history and physical examination, physicians have several options for arriving at a TDS diagnosis including questionnaires and a biochemical assessment from peripheral blood.
Clinical Assessment
TDS may encompass numerous, sometimes vague and non-specific symptoms and signs: a decreased sense of well-being; a decrease in muscle mass, strength, energy; reduced virility, libido, and sexual activity, increased frequency
225
Urologic Endocrinology
of impotence,increased sweating,mood changes, |
check the reference range for serum testoster- |
|
fat mass, dry skin and anemia.59 Other symp- |
one in the laboratory they use to help them |
|
toms are even less specific and include reduced |
interpret the results. Normal reference ranges |
|
erectile strength, fatigue, mood disturbances |
for serum total testosterone in adult men is gen- |
|
comprising of irritability, frustration, lack of |
erally considered to be 300–1,000 ng/dL (10– |
|
motivation and depression. Medical history |
35 nmol/L). Levels of <250 ng/dL (8.7 nmol/L) |
|
should be focused on the presence of pituitary |
suggest that the patient is likely to be hypogo- |
|
disease, primary testicular disease, exposure to |
nadal,whereaslevelsof >350 ng/dL(12.7nmol/L) |
|
radiation, failure to develop at puberty and |
suggest that the symptoms may not be due to |
|
osteoporosis. Physical examination may detect |
androgen deficiency. Some recent publications |
|
signs of hypogonadism such as lack of second- |
suggest using cut-off values of between 200 and |
|
ary sexual characteristics and fine wrinkling of |
400 ng/dL.61 When morning serum total testos- |
|
facial skin. In middle-aged to older men, the |
terone levels are <250 ng/dL, luteinizing hor- |
|
symptoms become even less specific because of |
mone (LH) and follicle stimulating hormone |
|
the higher frequency of co-morbid conditions. |
(FSH) levels should be checked. LH and FSH lev- |
|
Three questionnaires are most widely recog- |
els are elevated in primary hypogonadism but |
|
nized as improving diagnostic specificity: the |
are normal or low in secondary hypogonadism. |
|
St. Louis University Androgen Deficiency in |
If testosterone,LH,and FSH levels are low,serum |
|
Aging Males (ADAM) (Table 17.2), the Mass- |
prolactin should be checked to exclude a prolac- |
|
achusetts Aging Survey (MMAS), and the Aging |
tin-secreting pituitary tumor. The International |
|
Male Survey (AMS) (Table 17.3). |
Society of Andrology (ISA), International |
|
|
Society for the Study of the Aging Male (ISSAM), |
|
Biochemical Assessment |
and European Association of Urology (EAU) |
|
guidelines recommend that levels <231 ng/dL |
||
|
||
Clinicians should optimize the determination of |
(8 nmol/L) are representative of hypogonadism |
|
serum testosterone levels by drawing the blood |
and in such cases testosterone replacement may |
|
sample in the morning (between 7 and 10 a.m). |
therefore be appropriate while levels above a |
|
Although circadian rhythms in serum testoster- |
threshold of 346 ng/dL (12 nmol/L) are nor- |
|
one are less marked as men age, the reference |
mal.23 Borderline levels of total testosterone |
|
ranges are usually obtained in the morning in |
should be followed up by measurement of free |
|
younger men. In addition, physicians should |
or bioavailable testosterone. If these levels are |
Table 17.2. the st. louis University androgen deficiency in aging males (adaM) questionnaire (reprinted from carlo Bettocchi60; table 4, p. 7)
Questionnaire (circle one)
yes |
no |
(1) |
do you have a decrease in libido (sex drive)? |
yes |
no |
(2) |
do you have a lack of energy? |
yes |
no |
(3) |
do you have a decrease in strength and/or endurance? |
yes |
no |
(4) |
Have you lost height? |
yes |
no |
(5) |
Have you noticed a decreased enjoyment of life? |
yes |
no |
(6) |
are you sad and/or grumpy? |
yes |
no |
(7) |
are your erections less strong? |
yes |
no |
(8) |
Have you noticed a recent deterioration in your ability to play sports |
yes |
no |
(9) |
are you falling asleep after dinner? |
yes |
no |
(10) |
Has there been a recent deterioration in your work performance? |
a positive answer represent yes to (1) or (7) or any other three questions
226
Practical Urology: EssEntial PrinciPlEs and PracticE
Table 17.3. the aging males’ symptoms (aMs) scale (reprinted from carlo Bettocchi60 table 3, p. 7)
Symptoms |
|
Score |
|
|
|
|
|
|
|
1 |
2 |
|
3 |
4 |
5 |
1. |
decline in your feeling of general well-being |
|
|
|
|
|
|
|
(general state of health, subjective feeling) |
|
|
|
|
|
|
2. |
Joint pain and muscular ache (lower back pain, |
|
|
|
|
|
|
|
joint pain, pain in a limb, general back ache) |
|
|
|
|
|
|
3. |
Excessive sweating (unexpected/sudden episodes |
|
|
|
|
|
|
|
of sweating, hot flushes independent of strain) |
|
|
|
|
|
|
4. |
sleep problems (difficulty in falling asleep, |
|
|
|
|
|
|
|
difficulty in sleeping through, waking up early |
|
|
|
|
|
|
|
and feeling tired, poor sleep, sleeplessness) |
|
|
|
|
|
|
5. |
increased need for sleep, often feeling tired |
|
|
|
|
|
|
6. |
irritability (feeling aggressive, easily upset about |
|
|
|
|
|
|
|
little things, moody) |
|
|
|
|
|
|
7. |
nervousness (inner tension, restlessness, feeling |
|
|
|
|
|
|
|
fidgety) |
|
|
|
|
|
|
8. |
anxiety (feeling panicky) |
|
|
|
|
|
|
9. |
Physical exhaustion / lacking vitality (general |
|
|
|
|
|
|
|
decrease in performance, reduced activity, |
|
|
|
|
|
|
|
lacking interest in leisure activities feeling of |
|
|
|
|
|
|
|
getting less done, of achieving less of having to |
|
|
|
|
|
|
|
force oneself to undertake activities) |
|
|
|
|
|
|
10. |
decrease in muscular strength (feeling of |
|
|
|
|
|
|
|
weakness) |
|
|
|
|
|
|
11. |
depressive mood (feeling down, sad, on the verge |
|
|
|
|
|
|
|
of tears, lack of drive, mood swings, feeling |
|
|
|
|
|
|
|
nothing is of any use) |
|
|
|
|
|
|
12. |
Feeling that you have passed your peak |
|
|
|
|
|
|
13. |
Feeling burnt out, having hit rock-bottom |
|
|
|
|
|
|
14. |
decrease in beard growth |
|
|
|
|
|
|
15. |
decrease in ability/frequency to perform sexually |
|
|
|
|
|
|
16. |
decrease in the number of morning erections |
|
|
|
|
|
|
17. |
decrease in sexual desire/libido (lacking pleasure |
|
|
|
|
|
|
|
in sex, lacking desire for sexual intercourse) |
|
|
|
|
|
|
Have you got any other major symptoms? |
yes |
|
|
no |
|
|
|
if yes please describe: |
|
|
|
|
|
|
low, then the patient is a candidate for testosterone replacement therapy. Values between these limits warrant a repeat morning serum testosterone determination with direct measurement
of free testosterone by equilibrium dialysis or calculated by measurements of sex hormonebinding globulin (SHBG) and total testosterone levels.